The new facility will be exclusively used for curcumin extraction, increasing production of Curcumin C3 Complex to 25 tons from the previous capacity of 6 tons
Sabinsa’s parent company Sami Labs, which manufactures and markets phytonutrients and standardised herbal extracts, specialty fine chemicals and organic intermediates used in the nutritional, pharmaceutical and food industries, inaugurated a second continuous extraction plant on 5 October to meet demand for Curcumin C3 Complex.
The two continuous extraction units are spread across 5 acres in Dobaspet, Bangalore, India.
Seeking to avoid the seemingly ubiquitous artificial ingredients in the food and cosmetics industry, health conscious consumers have increased the demand for natural herbal extracts globally.
That preference for natural, accompanied by a robust body of research, has fuelled enormous growth in the curcumin extract market.
According to a new research report by Frost & Sullivan, the global curcumin market is expected to reach more than $100 million by 2023, which is growing at a CAGR of 12.6% from 2017 to 2023.
Although the demand for curcumin in dietary supplements, pharmaceuticals and cosmetics has experienced continuous growth, nutraceuticals make up more than 50% of the curcumin demand share, both by volume and revenue, and continue to grow faster than the other segments.
“Because of turmeric’s historic place in India’s traditional medical system, Ayurveda, India dominates world turmeric production, with 80% taking place here,“ said Dr Muhammed Majeed, founder and Chairman, Sami-Sabinsa Group.
“With our Curcumin C3 Complex, the world leader in curcumin ingredients, expanding extraction capacity to ensure that we can continue to meet demand was the logical next step.”